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Introduction
The advent of targeted therapies and immune checkpoint 
inhibitors (ICIs) has radically changed the therapeutic 
landscape of non-small cell lung cancer (NSCLC) over 
the last years, certainly contributing to the increase of 
5-year survival rate, reported to be 21.7% nowadays, 
compared to 17.2% about a decade ago (1). Although the 
efficacy of tyrosine kinase inhibitors (TKIs) is limited to 
a subset of NSCLC patients harboring specific oncogenic 
drivers, their implementation in the clinical practice 
dramatically improved patients’ survival and quality of life 
in stage IV diseases (2), delaying the use of less tolerated 
chemotherapeutic agents. Alongside epidermal growth 
factor receptor (EGFR), v-Raf murine sarcoma viral 
oncogene homolog B (BRAF), Kirsten rat sarcoma 2 viral 
oncogene homolog (KRAS) and c-MET-exon 14 mutations 
(hepatocyte growth factor receptor), oncogenic fusions 
involving anaplastic lymphoma kinase (ALK), v-ROS avian 
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UR2 sarcoma virus oncogene homolog 1 (ROS1), rearranged 
during transfection (RET), and tropomyosin receptor kinase 
A (NTRK) genes represent the most successfully druggable 
targets in NSCLC, with new-generation TKIs already 
available or coming soon in the clinical setting. This means 
to progressively extend the number of potential candidates 
to personalized treatment strategies in the upcoming years. 
Conversely, the majority of patients with oncogene-addicted 
NSCLC have been excluded from the “immunotherapy 
revolution”, due to the anticipated poor response from 
preclinical data (3) and the lack of activity observed in the 
small group of EGFR-positive patients included in the 
second-line ICIs clinical studies (4). As a consequence, the 
clinical development of ICIs, both as single agent and in 
combination with first-line platinum-based chemotherapy 
has been exclusively limited to the EGFR/ALK wild-type 
NSCLC population. In absence of prospective data on 
immune-chemotherapy combinations in oncogene-addicted 
NSCLC, a subgroup analysis of the phase III IMpower-150 
trial showed that the survival benefit derived from the 
addition of atezolizumab to the bevacizumab-chemotherapy 
combination regimen in advanced non-squamous NSCLC, 
was extended also to the EGFR-mutant population 
[hazard ratio (HR): 0.60; 95% confidence intervals (CIs): 
0.31–1.14] (5). This evidence has driven the regulatory 
approval of this treatment regimen after EGFR-TKI failure, 
but the low number of evaluated patients and the lack of 
detailed information regarding tumor molecular alterations 
and previous TKI lines reduced the scientific reliability and 
the clinical value of such data. Conversely, the prospect of 
further improving overall survival (OS) with the combination 
of TKIs and ICIs lead to unexpected poor results and 
safety issues in recent phase I trials exploring different drug 
associations. Based on current available clinical evidence, 
immunotherapy and TKIs are emerging as two different 
therapeutic approaches with clinical efficacy limited to two 
distinct, separate subsets of NSCLC patients. However, 
preclinical studies and translational data revealed interesting 
dynamic molecular networks between tumor cells intrinsic 
oncogenic signaling and immune microenvironment, with 
potential influence on immunomodulating process, which 
provide a strong rationale to pursue the investigation of ICI 
treatment efficacy in particular subsets of oncogene-addicted 
NSCLC. This review will particularly focus on the subgroup 
of patients whose disease harbors oncogenic rearrangements, 
summarizing current evidence from preclinical and clinical 
studies and discussing their practical implications, in order 
to define the potential role of ICIs therapy in the clinical 
management of fusion-driven NSCLC. We present the 
following article in accordance with the NARRATIVE 
REVIEW reporting checklist (available at http://dx.doi.
org/10.21037/tlcr-20-710).
Search strategy
The literature search was conducted using PubMed 
database. For each rearrangement analyzed in this review 
the following terms were used: “‘Rearrangement’ and PD-
L1 expression”, “‘Rearrangement’ and immunotherapy”, 
“‘Rearrangement’ and checkpoint inhibitors” and “NSCLC 
Fusions” (e.g., “ALK and checkpoint inhibitors”). Relevant 
studies published between January 2015 and May 2020 were 
selected. Literature citations within selected studies were 
also searched to find other potentially relevant studies.
ALK
The introduction of second-generation ALK inhibitors 
into clinical practice has dramatically improved the survival 
outcomes of ALK-positive NSCLC, with unmatched results 
even compared to other oncogene-addicted NSCLC. 
Alectinib and brigatinib have largely replaced crizotinib as 
first line treatment in ALK-positive patients with advanced 
disease, based on the results of the phase III ALEX (6) 
and ALTA-1L (7) trial, respectively. Lorlatinib is the first 
third-generation ALK inhibitor that has been approved as 
a second line treatment after ALK-TKI progression in this 
subgroup of patients, based on the B7461001 phase II trial 
results (8). Nowadays, the treatment algorithm for advanced 
ALK-positive NSCLC should include a second-generation 
TKIs (alectinib or brigatinib preferred over ceritinib) in first 
line therapy, eventually followed by lorlatinib or platinum-
based chemotherapy at disease progression. Immunotherapy 
represent a potential option in heavily pre-treated patients 
who maintain a good performance status.
Pre-clinical background
Several studies illustrated the correlation between ALK-
rearrangements and programmed death ligand-1 (PD-
L1) expression. PD-L1 mRNA and surface protein 
expression are significantly higher in EML4-ALK-positive 
lines compared to both EGFR and ALK wild-type cells. 
Moreover, wild-type cells transfected with an EML4-ALK 
expression vector showed an increase of PD-L1 levels, while 
alectinib downregulated PD-L1 expression in EML4-ALK-
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positive models (9). PD-L1 TPS score usually increased in 
repeated biopsy after ALK-TKIs therapies, reaching about 
57% in heavily pre-treated samples (10).
I t  ha s  been  l a rge ly  demons t r a t ed  tha t  ALK-
rearrangements upregulates PD-L1 expression via STAT3 
signaling in both anaplastic large cell lymphoma (11) and 
lung cancer (12). Indeed, PD-L1 expression significantly 
decreased in EML4-ALK-positive cell lines when treated 
with STAT3 inhibitors. Data from protein-DNA binding 
assays suggest that STAT3 exerts its activity by directly 
binding to PD-L1 promoter region. Marzec et al. used 
CRISPR/Cas9 library screening to find other nuclear 
proteins (GRB2/SOS1, IRF4, BATF3) that play a crucial 
role for ALK-mediated PD-L1 expression in NPM-ALK-
positive anaplastic large-cell lymphoma (11). Indeed, these 
transcription factors seem to be equally involved for the PD-
L1 upregulation in EML4-ALK-positive adenocarcinomas 
(ADCs). HIF-1α cooperates with STAT3 to increase PD-
L1 levels under hypoxia. While HIF-1α is known to act as a 
transcription factor for PD-L1 in different tumor types (13), 
its effect seems to be amplified in EML4-ALK-positive lung 
cancer. The interaction between STAT3 and HIF-1α might 
be critical to enhance PD-L1 expression in EML4-ALK-
positive cell lines (12). Recently, Nouri et al. identified ALK 
as a critical regulator of the Hyppo pathway, which seems 
to be involved in both tumorigenesis and immune evasion 
processes (14). The interaction between EML4-ALK and 
the yes-associated protein 1/transcriptional co-activator 
with PDZ binding motif (YAP/TAZ) complex resulted in a 
STAT3 independent PD-L1 upregulation (14).
Correlations between ALK-rearrangements and other 
known immune-related biomarkers, such as CD8+ T cell 
infiltration, HLA-class I receptor expression and total 
mutation burden (TMB), have been also investigated. The 
combination of PD-L1 expression on tumor or stromal 
cells and intratumoral infiltration by PD-1+CD8+ T cells 
tended to be more frequent in ALK-positive than in non-
ALK-rearranged ADCs. In addition, high HLA-class I 
expression on tumor cells with intratumoral infiltration by 
PD-1+/CD8+ T cells appeared to be more frequent in ALK-
positive ADCs (15). Interestingly, a positive correlation 
between intratumoral infiltration by CD8+ T cells and 
ALK-rearrangements was not constantly observed in other 
tumors (16). Conversely, TMB level was significantly 
lower (mean 3.1 mutation/Mb) in ALK-positive lung 
cancer compared to that observed in unselected NSCLC 
patients (17). Although a prognostic role of these biomarkers 
in ALK-rearranged NSCLC has not been demonstrated 
yet (15), in a large retrospective database including 715 
EGFR/ALK-positive lung cancer samples, with only 10% 
reporting ALK-rearrangement, the detection of PD-L1+/
CD8+ cells in the tumor microenvironment was associated 
to worse OS (44.3 months compared with 93.4 months 
in PD-L1–/CD8– group) (18). Finally, pre-clinical data 
showed that the therapeutic inhibition of ALK oncogenic 
signaling increased T-cells interactions, proliferation and 
tumor infiltration, as well as inflammatory cytokine release, 
thus providing biological rationale for immune-target 
combination strategies (19).
Clinical evidence
Despite the theoretically favorable preclinical background, 
available evidence from different trials testing ICIs for 
ALK-rearranged ADCs have so far been disappointing. 
ICIs have been investigated either alone (prospectively and 
retrospectively) or in combination with chemotherapy or 
ALK-TKIs (Table 1).
ALK-positive ADCs, as well as other oncogene addicted 
NSCLC, were poorly represented in the majority of 
prospective clinical trials investigating single agent ICI both 
in second and first-line setting (20-22). The ATLANTIC 
study was a single arm trial investigating durvalumab in 
NSCLC patients who received at least two previous lines 
of treatment. In the Cohort 1, 111 patients with ALK and/
or EGFR positive NSCLC were enrolled, including 16 
patients with ALK-positive ADCs. Exclusive analysis for 
OS in the ALK-positive subgroup was not performed, but 
an exploratory post-hoc analysis showed that all objective 
responses in the cohort 1 occurred in EGFR+ patients 
(9%; 10 out of 111) (23). Only five EML4-ALK-positive 
patients were included in the OAK trial, comparing 
atezolizumab vs. docetaxel in previously treated NSCLC, 
while about 50% of the entire population was untested for 
ALK-rearrangements (24). Thus, any evaluation about the 
efficacy of atezolizumab in this subgroup is meaningless. 
The Impower-150 investigated the association between 
atezolizumab and bevacizumab with standard platinum-
based chemotherapy in non-squamous NSCLC. Thirty-four 
patients with EML4-ALK-positive disease, experiencing 
disease progression to at least one previous treatment, were 
enrolled in the trial (13 in the experimental arm). In EGFR/
ALK-positive population progression-free survival (PFS) 
and OS were longer within the chemo-immunotherapy 
combination compared to control arm (PFS: median, 8.3 vs. 
6.8 months; HR, 0.61; 95% CI, 0.52 to 0.72; OS: median, 
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9.7 vs. 6.1 months; HR, 0.59; 95% CI, 0.37 to 0.94) (25). 
Considering the low number of included patients and the 
lack of efficacy analysis specifically devoted to ALK-positive 
subgroup, the exact efficacy of this combination in TKI-
pre-treated patients with ALK-rearrangements remains 
currently controversial. A phase II prospective study is 
currently evaluating the efficacy of pembrolizumab in 
combination with platinum-based doublet chemotherapy 
in patients with ALK-rearranged NSCLC with progressive 
disease following prior TKIs (NCT03242915).
Additional data were available from retrospective studies 
and small case series. Among 551 pre-treated patients with 
advanced NSCLC included in the IMMUNOTARGET 
registry, 23 harbored ALK-rearrangements. All patients 
received a programmed death-1 (PD-1) or PD-L1 inhibitor 
at some point of their disease history, especially as a second- 
or third-line treatment (67%), and objective responses were 
not observed in anyone of the ALK-positive patients (26). 
These results are consistent with another retrospective 
series of 13 ALK-positive patients collected by Ng et al., 
Table 1 ICIs activity and safety in fusion-driven NSCLC patients
Authors [year] N. patients Treatment ORR AEs grade ≥3
ALK
Mazieres et al. [2019] 23 PD-1/PD-L1 inhibitors 0% NR
Ng et al. [2019] 13 PD-1/PD-L1 inhibitors 0% NR
Gainor et al. [2016] 6 PD-1/PD-L1 inhibitors 0% NR
Heo et al. [2019] 14 PD-1/PD-L1 inhibitors 14.3% NR
Bylicki et al. [2020] 8 PD-1/PD-L1 inhibitors 25% 8%**
Chalmers et al. [2019] 3 Crizotinib-ipilimumab NR* 33%
Spigel et al. [2018] 13 Crizotinib-nivolumab 38%* 38%
Patel et al. [2020] 9 Crizotinib-pembrolizumab 55.6% 44%
Felip et al. [2020] (TKI naïve) 16 Ceritinib-nivolumab 69% 36%
Felip et al. [2020] (pre-treated) 20 Ceritinib-nivolumab 35%
Kim et al. [2018] 21 Alectinib-atezolizumab 85.7% 57%
Shaw et al. [2018] 28 Lorlatinib-avelumab 46.4% 53.6%
ROS1
Mazieres et al. [2019] 7 PD-1/PD-L1 inhibitors 17% NR
Park et al. [2018] 12 CTLA4/PD-1/PD-L1 inhibitors 25% NR
RET
Offin et al. [2019] 16 CTLA4/PD-1/PD-L1 inhibitors 0% NR
Mazieres et al. [2019] 16 PD-1/PD-L1 inhibitors 6% NR
Guisier et al. [2020] 9 PD-1/PD-L1 inhibitors 37.5% 10%**
Sarfaty et al. [2017] 2 Pembrolizumab 0% NR
Lu et al. [2020] 10 CTLA4/PD-1/PD-L1 inhibitors 20% NR
NRG1
Duruisseaux et al. [2019] 6 PD-1/PD-L1 inhibitors 0% NR
*, treatment discontinued due to safety issues; **, overall population enrolled in the trial, included but not limited to ALK/RET positive 
NSCLC. ICI, immune-checkpoint inhibitor; NSCLC, non-small cell lung cancer; N., number; ORR, objective response rate; AEs, adverse 
events; PD-1, programmed death-1; PD-L1, programmed death ligand-1; CTLA-4, cytotoxic T-lymphocyte antigen 4; NR, not reported.
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where no response were achieved (27). Similar findings 
from other small series were reported, with overall response 
rate (ORR) to PD-1 blockade overall ranging from 0% to 
25% in the ALK-rearranged population (28-30).
Despite a strong biological rationale and the high 
expectations regarding the association between TKI and 
immunotherapy, phase I clinical trials disappointing results 
discouraged to pursue this treatment strategy. In a phase 
1 trial the CTLA4 inhibitor ipilimumab was studied in 
combination with erlotinib or crizotinib in EGFR and 
ALK-positive NSCLC, respectively. Both treatment arms 
were associated to unacceptable toxicity, with two of three 
ALK-positive patients developing hypophysitis and grade 
2 pneumonia, respectively (31). Combinations of TKIs 
and PD1/PDL1 inhibitors were also characterized by high 
grade adverse events. CheckMate 370 was a 5-cohort, open-
label phase 1/2 study investigating nivolumab in different 
settings. Within the cohort E, nivolumab (240 mg every 
2 weeks) was associated with crizotinib (250 mg twice daily) 
as a first line therapy for advanced ALK-positive NSCLC. 
Among the 13 patients enrolled in the study, 5 (38%) 
developed severe hepatic toxicities, including two grade 
5 toxicities. Hepatic adverse events were reported to be 
less common with single agent nivolumab (0.3% to 1.5%) 
(20,32) and crizotinib (2.3%) (33), suggesting an additive 
and synergistic toxic effect for the combination. Enrolment 
was closed and treatment discontinued in all other patients 
included in this cohort (34). Another trial investigating 
the association of pembrolizumab and crizotinib was 
terminated early due to the very slow accrual. Elevations in 
transaminase levels was the most common adverse event, 
but bilirubin increase or hepatic failure was not observed in 
this study, as toxicities were reversible with pembrolizumab 
discontinuation (35). Ceritinib and nivolumab combination 
was evaluated in an open-label, phase 1B study. The trial 
enrolled 16 TKI-naïve and 20 pre-treated ALK-positive 
patients to receive nivolumab (3 mg/kg every 2 weeks) 
plus ceritinib (three different dose levels, administrated 
once daily with a low-fat meal). Despite the study planned 
a maximum dose of 600 mg/day for ceritinib, all patients 
received 300 mg/die (n=22) or 450 mg/die (n=14). Once 
again, a high rate (83%) of grade ≥3 adverse events was 
reported, with increase in AST/ALT or lipase levels, and 
rash being the most common. ORR and PFS were 69% and 
16.6 months in the TKI-naïve and 35% and 4.6 months in 
the pre-treated subgroups, respectively (36). Although the 
combination showed some level of activity, particularly in 
presence of high PD-L1 expression, overall results were 
comparable to those obtained with ceritinib monotherapy in 
the ASCEND-4 and ASCEND-5 trials, with the drawback 
of augmented toxicities (37,38). In another phase I trial, 
induction therapy with alectinib at the standard dose of 
600 mg BID for a week was followed by the association of 
alectinib (600 mg BID) and atezolizumab (1,200 mg every 
3 weeks) (39). Twenty-one ALK-positive patients who had 
not received any previous treatment were enrolled in the 
study. Since the median follow-up at the time of data cut off 
was just 13 months and considering the impressive outcome 
in terms of PFS reported with alectinib monotherapy in 
the ALEX trial (40), any assumption about the activity 
of this combination remains speculative. Conversely, 
the tolerability profile of the association was really poor, 
compared to single agent TKI, with 14 patients (67%) 
experiencing alectinib dose interruptions or modifications 
due to grade 3 adverse events (57.1% treatment-related, 
mainly rash and liver toxicity). Lastly, Javelin Lung 101 
trial evaluated the combination of avelumab with crizotinib 
or lorlatinib in two different cohorts. The combination 
of avelumab and crizotinib was investigated in the ALK 
wild-type population. The avelumab-lorlatinib cohort 
included 28 ALK-positive patients, reaching an ORR of 
46.4%, which could be considered a promising result in a 
population with unfavorable prognostic factors (36% had 
untreated brain metastasis, 71.4% received two or more 
previous TKIs) (41). The safety was again the main issue 
with grade ≥3 adverse events occurring in 53.6% of cases.
ROS1
ROS1 tyrosine kinase domains present high affinity with the 
ALK ones, therefore TKIs targeting ALK-rearrangements, 
crizotinib and lorlatinib, showed great levels of activity also 
in ROS1 positive patients (42,43). Entrectinib is a novel 
TKI that inhibits both ROS1 and NTRK fusion products, 
showing great efficacy in a heterogeneous group of ROS1 
positive NSCLC included in an integrative analysis of three 
phase I/II trials. (44). Promising results were reported in 
early-phase clinical trials for repotrectinib and DS-6051b 
(45,46). Since crizotinib represents the current first-line 
standard of care in this subgroup of patients, single agent 
immunotherapy could be considered in patients progressed 
to previous TKI and chemotherapy.
Pre-clinical background
The correlation between ROS1 rearrangements and PD-
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L1 expression or immunotherapy response is the least 
investigated so far among the druggable translocations in 
NSCLC. While ROS1 and ALK present high homology in 
their kinase domains, suggesting a similar effect on PD-L1 
expression, there are current no preclinical data confirming 
this hypothesis. ROS1 positive tumors were poorly 
represented even in retrospective case series (27,47,48), 
preventing any conclusion about PD-L1 expression in 
this subgroup of patients. Importantly, ROS1 positive 
NSCLC shares with ALK- and RET- positive counterparts 
a lower TMB compared to wild type or EGFR-mutated 
adenocarcinomas (49).
Clinical evidence
Seven ROS1 positive NSCLC patients were enrolled within 
the IMMUNOTARGET cohort. ORR was 17%, while 
PFS and OS data were not available (26). In a retrospective 
Korean study 12 ROS1 positive NSCLC patients (among 
103, 67% stage IV) received ICIs at some point of their 
treatment history. ORR was 25% and PFS ranged 
from 1.1 to 10.7 months (50) (Table 1). The presence of 
ROS1 positive NSCLC in prospective phase III trials 
investigating ICIs both as single agent and as combination 
with chemotherapy was not assessed, while phase I trials 
investigating crizotinib/lorlatinib and ICIs combinations 
were limited to ALK-positive patients.
RET
RET-rearranged NSCLC is getting more and more 
interest among clinicians with the upcoming advent of 
new selective RET inhibitors. Thus, searching for RET 
fusions is becoming more common in clinical practice 
alongside EGFR and BRAF mutations and ALK and ROS1 
rearrangements. Pralsetinib (BLU-667) and selpercatinib 
(LOXO-292), are the two major compounds currently under 
clinical development, with promising activity emerging 
from the ARROW (51) and the LIBRETTO-001 (52) 
phase 1 trials, respectively. A phase III trial comparing 
selpercatinib to platinum-based chemotherapy with or 
without pembrolizumab as a first line treatment in RET 
positive NSCLC is currently ongoing (LIBRETTO-431, 
NCT04194944). Where clinical trials for selective 
RET inhibitors are not available, chemotherapy and/or 
immunotherapy remains the current standard first line 
treatment for RET positive NSCLC.
Pre-clinical background
As a recent molecular alteration for NSCLC, potential 
correlation between RET and PD-L1 expression has 
not been investigated yet on molecular basis. However, 
RET signaling pathway includes STAT family members 
(STAT1/3/5) (53), which are known to increase PD-
L1 expression, as already stated above. In addition, data 
from studies on multiple endocrine neoplasia type 2 
showed that RET positive papillary thyroid carcinoma 
display a significant immune infiltrate in the tumor 
microenvironment (54). Whether these results are 
applicable also to NSCLC remains uncertain. RET positive 
NSCLC presented significant PD-L1 expression in 
different case series (49,55-57), with PD-L1 positive (TPS 
≥1%) RET-rearranged tumors accounting for 40–50% of 
all cases. Conversely, median TMB was significantly lower 
in RET positive as compared to wild type NSCLC (49,56), 
but similar to that reported for ALK and ROS1 positive 
NSCLC (49).
Clinical evidence
Screening for RET rearrangements was not required in 
the main prospective NSCLC trials with single agent ICIs 
or chemo-immunotherapy combinations, thus the number 
of RET positive cases enrolled, if any, as well as potential 
ICI efficacy in this subgroup of enrolled patients, remains 
currently unknown. Several retrospective series reported 
generally poor response to ICIs. Offin et al. collected 74 
RET positive NSCLC patients, with 16 of them receiving 
PD-1/PD-L1 inhibitors at some point of their treatment 
history. No objective response was observed among the 13 
patients assessed for clinical and/or radiological response 
and overall PFS was 3.4 months (56). These results are 
consistent with the RET cohort included within the 
IMMUNOTARGET registry, where only one of 16 
evaluated patients achieved PR, with median PFS reaching 
2.1 months (26). In another retrospective case series, two 
RET positive patients (out of 14 total cases) with PD-L1 
TPS >50% received pembrolizumab as first line therapy. 
PD was observed for both patients after 1 and 2 months 
respectively (58). Baglivo et al. reported two cases of RET 
positive NSCLC with PD-L1 expression >50% who 
experienced hyper-progression under Pembrolizumab 
first line therapy, suggesting that knowing RET status 
at baseline could be crucial to exclude these patients 
from immunotherapy treatment (59). More encouraging 
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results were obtained by Guisier et al. in a small subgroup 
of nine RET-positive NSCLC patients who received 
pembrolizumab or nivolumab (89% as a second- or third-
line therapy). Three patients achieved partial response and 
the disease control rate and PFS were 60% and 7.6 months 
respectively (57). Lastly, 11 patients received ICIs among 
129 RET-rearranged NSCLC collected in 13 Chinese 
centers. Among 10 patients with evaluable response, disease 
control rate was 60%, and ORR was 20%. PFS was overall 
poor (3.8 months), but two patients had durable response 
of 10.4 and 11.5 months at data cut off. Interestingly, both 
patients harbored KIF5B-RET fusion and presented high 
PD-L1 expression (TPS >50%) (49) (Table 1). Efficacy 
of combinations between immunotherapy and selective 
RET inhibitors have not been assessed yet. As far as we 
know, there are not ongoing clinical trials evaluating this 
treatment strategy.
Emerging oncogene rearrangements
Neurotrophic tyrosine kinase- (NTRK), neuregulin 
1- (NRG1), and fibroblast growth factor receptor 3- 
(FGFR3) fusions have been recently proposed as novel 
oncogene drivers for a small percentage of NSCLC (60-63). 
Selective TKIs targeting NTRK rearrangements, like 
entrectinib and larotrectinib, are currently being tested 
for several tumor types, (60) with both agents showing 
exciting activity also for NTRK positive NSCLC (64,65). 
However, where clinical trials for NTRK inhibitors are not 
available, chemotherapy and/or immunotherapy remains 
the standard first line treatment options for NTRK positive 
NSCLC. Alongside c-MET amplification and exon 14 
skipping mutation, KIF5B-MET, HLA-DRB1-MET, and 
MET-ATXN7L1 fusions have also been recently reported 
as oncogenic drivers in NSCLC (66-68). The clinical 
relevance of these rearrangements is still unclear, but their 
onset could be unrelated to other oncogene alterations 
and previous TKI treatments. Although novel TKIs are 
currently being tested for the different c-MET alterations, 
MET fusions have been excluded from the majority of 
these clinical trials (e.g., NCT02864992, NCT04077099, 
NCT03940703, NCT03911193).
Pre-clinical background
Comprehensive genomic profiling showed a higher TMB 
and PD-L1 expression for NTRK rearranged NSCLC 
compared to other oncogene addicted tumors harboring 
EGFR mutations, ALK or ROS1 rearrangements (69). 
However, NTRK fusions in NSCLC often co-exist with 
STK11 mutations, which have been associated to poor 
immunotherapy response in KRAS mutant disease (70). 
A global, multicenter network of thoracic oncologists 
(6 countries, 13 institutions) identified 80 patients with 
pathologically confirmed NRG1 fusion-positive NSCLCs; 
when tested, PD-L1 was found negative in most of these 
tumors (79%, 26/33) (71). Qin et al. evaluated TMB in FGFR 
rearranged NSCLC, showing relatively low levels (5.2 Mb), 
in the majority of tested adenocarcinomas, consistently 
with the results obtained for other oncogene addicted 
NSCLC. As expected, TMB was higher in squamous 
cell carcinomas (9.6 Mb) (63). c-MET activation induces 
PD-L1 expression regardless from JAK/STAT signaling 
pathway (72,73). It was associated also to the upregulation 
of other immunosuppressive genes and transcripts involved 
in angiogenesis and cell proliferation (72). Moreover, 
Wang et al. demonstrated that the inhibition of c-MET 
decreased indoleamine-2,3-dioxygenase expression (74), 
which exerts immunosuppressive effects on T-cells and 
natural killer cells (75). These data suggest that MET 
activation could be involved in the tumors immune escape 
process, likely contributing to an immunosuppressive 
microenvironment (76). Although specific conclusions for 
MET fusions cannot be currently drawn, it is likely that the 
high PD-L1 expression and low-TMB level found in c-MET 
exon 14 skipping mutated NSCLC samples (77) may be 
likely applied also to other MET alterations, including 
oncogenic rearrangements.
Clinical evidence
Duruisseaux et al. observed no ORR among 6 NSCLC 
patients harboring NRG1 fusions who were treated with 
anti-PD-1 or anti-PD-L1 therapy (71). Although the high 
frequency of high PD-L1 expression, single agent ICIs 
activity in c-MET exon 14 skipping mutated NSCLC 
patients was very poor within different retrospective series 
(26,77), while favorable outcomes to ICIs therapy have been 
observed in patients with high c-MET expression (78). No 
evidence is currently available regarding the clinical efficacy 
of ICIs in MET, NTRK, or FGFR3 rearranged NSCLCs.
Conclusions
The potential role of ICI therapy in NSCLC patients 
harboring oncogenic fusions represents an actual and 
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controversial topic which requires further investigation 
in dedicated studies. Pre-clinical data revealed that ALK/
ROS1/RET rearranged NSCLC are mostly characterized 
by low TMB level, suggesting that high PD-L1 expression 
may just be an epiphenomenon of the oncogene pathway 
activity rather than a crucial mechanism of cancer immune-
escape. Current available evidence (Table 1) overall showed 
that tumors harboring oncogene rearrangements likely do 
not represent the best candidate to single agent ICI therapy, 
with poor clinical responses to PD1/PD-L1 inhibitors 
reported across different retrospective studies including 
TKI pre-treated populations. The higher incidence of 
rare oncogene rearrangements may likely explain also the 
lower efficacy of first-line ICIs in never smoker patients 
with high PD-L1 expression (79), highlighting the issue 
of adequate molecular testing for upfront treatment 
selection. Despite a strong biological rationale and the 
high expectation regarding the association between TKI 
and immunotherapy, early clinical trials disappointing 
results discouraged to pursue this treatment strategy. 
Combination therapy with next-generation TKIs, which are 
usually associated to a lower toxicity, could still represents 
a viable option, worthy of investigation in dedicated trials. 
However, the specific impact of immunotherapy on already 
long-lasting TKI-related response might be difficult 
to prove and a serious evaluation of cost/effectiveness 
ratio, also in terms of financial toxicities, is mandatory. 
Considering the recent advent of immune-chemotherapy 
regimens in clinical practice, exploring the potential 
efficacy of this treatment strategy in specific subsets of 
NSCLC patients harboring oncogenic fusions represents a 
major topic for clinical research. Although the occurrence 
of ALK/ROS1 secondary mutations represent the main 
resistance mechanisms emerging under TKI therapy 
(80,81), however, a significant subgroup of ALK/ROS1+ 
NSCLC patients treated with second/first-generation 
TKI, and most of those treated with third-generation TKI 
develop a non-oncogene driver dependent mechanism 
of resistance, being the best candidate for a combination 
approach (82). Furthermore, the recent evidence that 
lorlatinib activity after second-generation TKI resistance 
is strictly dependent from the presence of secondary ALK 
mutations (83) is leading to the development of genomic-
driven therapeutic sequences in ALK/ROS1 positive 
NSCLC patients, ultimately favoring the investigation of 
alternative strategies in mutation-negative subgroups. The 
large-scale spreading of next generations sequencing panels 
will likely lead to an increased detection of rare oncogene 
rearrangement in NSCLC, with a potential correlation to 
both PD-L1 expression and ICIs’ efficacy. Considering 
the low prevalence of oncogenic fusions in the overall 
NSCLC population, the design of prospective clinical 
studies in this subset of patients represents a real challenge 
for the academic community, but remains the best way 
to definitively assess whether there will be any place for 





Provenance and Peer Review: This article was commissioned 
by the Guest Editors (Silvia Novello, Francesco Passiglia) 
for the series “Looking for Chimeras in NSCLC: Widen 
Therapeutic Options Targeting Oncogenic Fusions” 
published in Translational Lung Cancer Research. The article 
was sent for external peer review organized by the Guest 
Editors and the editorial office.
Reporting Checklist: The authors have completed the 
NARRATIVE REVIEW reporting checklist. Available at 
http://dx.doi.org/10.21037/tlcr-20-710
Peer Review File: Available at http://dx.doi.org/10.21037/
tlcr-20-710
Conflicts of Interest: All authors have completed the 
ICMJE uniform disclosure form (available at http://
dx.doi.org/10.21037/tlcr-20-710). The series “Looking 
for Chimeras in NSCLC: Widen Therapeutic Options 
Targeting Oncogenic Fusions” was commissioned by the 
editorial office without any funding or sponsorship. SN 
serves as an unpaid editorial board member of Translational 
Lung Cancer Research from Jul 2014 to Jul 2021. SN and 
FP served as the unpaid Guest Editors of the series. FP 
reports personal fees from MSD, Boehringer Ingelheim, 
and Astra Zeneca, outside the submitted work. SN reports 
personal fees from Eli Lilly, MSD, Roche, BMS, Takeda, 
Pfizer, Astra Zeneca, and Boehringer Ingelheim, outside 
the submitted work. PB reports personal fees from Astra 
Zeneca, MSD, BMS, and Roche, outside the submitted 
work. The other authors have no other conflicts of interest 
to declare.
2682 Leone et al. Immunotherapy in fusion-driven NSCLC
© Translational Lung Cancer Research. All rights reserved.   Transl Lung Cancer Res 2020;9(6):2674-2685 | http://dx.doi.org/10.21037/tlcr-20-710
Ethical Statement: The authors are accountable for all 
aspects of the work in ensuring that questions related 
to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved.
Open Access Statement: This is an Open Access article 
distributed in accordance with the Creative Commons 
Attribution-NonCommercial-NoDerivs 4.0 International 
License (CC BY-NC-ND 4.0), which permits the non-
commercial replication and distribution of the article with 
the strict proviso that no changes or edits are made and the 
original work is properly cited (including links to both the 
formal publication through the relevant DOI and the license). 
See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
1. ASCO. 2019 State of Lung Cancer Report Released. 
Accessed 17 May 2020.
2. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed 
assays of oncogenic drivers in lung cancers to select 
targeted drugs. JAMA 2014;311:1998-2006.
3. Garrido G, Rabasa A, Garrido C, et al. Preclinical 
modeling of EGFR-specific antibody resistance: oncogenic 
and immune-associated escape mechanisms. Oncogene 
2014;33:3129-39.
4. Lee CK, Man J, Lord S, et al. Checkpoint inhibitors in 
metastatic EGFR-mutated non-small cell lung cancer—a 
meta-analysis. J Thorac Oncol 2017;12:403-7.
5. Kowanetz M, Socinski MA, Zou W, et al. Abstract 
CT076: IMpower150: Efficacy of atezolizumab (atezo) 
plus bevacizumab (bev) and chemotherapy (chemo) in 1L 
metastatic nonsquamous NSCLC (mNSCLC) across key 
subgroups. Chicago: Proceedings: AACR Annual Meeting 
2018, 2018:14-8.
6. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus 
crizotinib in untreated ALK-positive non-small-cell lung 
cancer. N Engl J Med 2017;377:829-38.
7. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus 
crizotinib in ALK-positive non-small-cell lung cancer. N 
Engl J Med 2018;379:2027-39.
8. Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in 
patients with ALK-positive non-small-cell lung cancer: 
results from a global phase 2 study. Lancet Oncol 
2018;19:1654-67.
9. Ota K, Azuma K, Kawahara A, et al. Induction of PD-
L1 Expression by the EML4-ALK Oncoprotein and 
Downstream Signaling Pathways in Non-Small Cell Lung 
Cancer. Clin Cancer Res 2015;21:4014-21.
10. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the 
treatment of non-small-cell lung cancer. N Engl J Med 
2015;372:2018-28. 
11. Marzec M, Zhang Q, Goradia A, et al. Oncogenic kinase 
NPM/ALK induces through STAT3 expression of 
immunosuppressive protein CD274 (PD-L1, B7-H1). 
Proc Natl Acad Sci 2008;105:20852-7.
12. Koh J, Jang JY, Keam B, et al. EML4-ALK enhances 
programmed cell death-ligand 1 expression in pulmonary 
adenocarcinoma via hypoxia-inducible factor (HIF)-1α and 
STAT3. Oncoimmunology 2015;5:e1108514.
13. Noman MZ, Desantis G, Janji B, et al. PD-L1 is a novel 
direct target of HIF-1α, and its blockade under hypoxia 
enhanced MDSC-mediated T cell activation. J Exp Med 
2014;211:781-90.
14. Nouri K, Azad T, Lightbody E, et al. A kinome-wide 
screen using a NanoLuc LATS luminescent biosensor 
identifies ALK as a novel regulator of the Hippo 
pathway in tumorigenesis and immune evasion. FASEB J 
2019;33:12487-99.
15. Roussel H, De Guillebon E, Biard L, et al. 
Composite biomarkers defined by multiparametric 
immunofluorescence analysis identify ALK-positive 
adenocarcinoma as a potential target for immunotherapy. 
Oncoimmunology 2017;6:e1286437.
16. Cha YJ, Shim HS. PD-L1 expression and CD8+ 
tumor-infiltrating lymphocytes are associated with 
ALK rearrangement and clinicopathological features 
in inflammatory myofibroblastic tumors. Oncotarget 
2017;8:89465-74.
17. Spigel DR, Schrock AB, Fabrizio D, et al. Total mutation 
burden (TMB) in lung cancer (LC) and relationship with 
response to PD-1/PD-L1 targeted therapies. J Clin Oncol 
2016;34:9017.
18. Liu SY, Dong ZY, Wu SP, et al. Clinical relevance of PD-
L1 expression and CD8+ T cells infiltration in patients 
with EGFR-mutated and ALK-rearranged lung cancer. 
Lung Cancer 2018;125:86-92.
19. Zhou P, Shaffer DR, Alvarez Arias DA, et al. In vivo 
discovery of immunotherapy targets in the tumour 
microenvironment. Nature 2014;506:52-7.
20. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus 
docetaxel in advanced nonsquamous non-small-cell lung 
cancer. N Engl J Med 2015;373:1627-39.
21. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab 
versus docetaxel for previously treated, PD-L1-positive, 
advanced non-small-cell lung cancer (KEYNOTE-010): a 
2683Translational Lung Cancer Research, Vol 9, No 6 December 2020
© Translational Lung Cancer Research. All rights reserved.   Transl Lung Cancer Res 2020;9(6):2674-2685 | http://dx.doi.org/10.21037/tlcr-20-710
randomised controlled trial. Lancet 2016;387:1540-50.
22. Reck M, Rodríguez-Abreu D, Robinson AG, et al. 
Updated analysis of KEYNOTE-024: pembrolizumab 
versus platinum-based chemotherapy for advanced non-
small-cell lung cancer with PD-L1 tumor proportion score 
of 50% or greater. J Clin Oncol 2019;37:537-46.
23. Garassino MC, Cho BC, Kim JH, et al. Durvalumab as 
third-line or later treatment for advanced non-small-cell 
lung cancer (ATLANTIC): an open-label, single-arm, 
phase 2 study. Lancet Oncol 2018;19:521-36.
24. Fehrenbacher L, von Pawel J, Park K, et al. Updated 
efficacy analysis including secondary population results 
for OAK: a randomized phase III study of atezolizumab 
versus docetaxel in patients with previously treated 
advanced non-small cell lung cancer. J Thorac Oncol 
2018;13:1156-70.
25. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab 
for first-line treatment of metastatic nonsquamous 
NSCLC. N Engl J Med 2018;378:2288-301.
26. Mazieres J, Drilon A, Lusque A, et al. Immune 
checkpoint inhibitors for patients with advanced lung 
cancer and oncogenic driver alterations: results from the 
IMMUNOTARGET registry. Ann Oncol 2019;30:1321-8.
27. Ng TL, Liu Y, Dimou A, et al. Predictive value of 
oncogenic driver subtype, programmed death-1 ligand 
(PD-L1) score, and smoking status on the efficacy of 
PD-1/PD-L1 inhibitors in patients with oncogene-driven 
non-small cell lung cancer. Cancer 2019;125:1038-49.
28. Gainor JF, Shaw AT, Sequist LV, et al. EGFR mutations 
and ALK rearrangements are associated with low 
response rates to PD-1 pathway blockade in non-small 
cell lung cancer: a retrospective analysis. Clin Cancer Res 
2016;22:4585-93.
29. Heo JY, Park C, Keam B, et al. The efficacy of immune 
checkpoint inhibitors in anaplastic lymphoma kinase-
positive non-small cell lung cancer. Thorac Cancer 
2019;10:2117-23.
30. Bylicki O, Guisier F, Monnet I, et al. Efficacy and safety 
of programmed cell-death-protein-1 and its ligand 
inhibitors in pretreated patients with epidermal growth-
factor receptor-mutated or anaplastic lymphoma kinase-
translocated lung adenocarcinoma. Medicine (Baltimore) 
2020;99:e18726.
31. Chalmers AW, Patel S, Boucher K, et al. Phase I trial 
of targeted EGFR or ALK therapy with ipilimumab in 
metastatic NSCLC with long-term follow-up. Target 
Oncol 2019;14:417-21.
32. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus 
docetaxel in advanced squamous-cell non-small-cell lung 
cancer. N Engl J Med 2015;373:123-35.
33. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib 
versus chemotherapy in ALK-positive lung cancer. N Engl 
J Med 2014;371:2167-77.
34. Spigel DR, Reynolds C, Waterhouse D, et al. Phase 
1/2 study of the safety and tolerability of nivolumab 
plus crizotinib for the first-line treatment of anaplastic 
lymphoma kinase translocation - positive advanced non-
small cell lung cancer (CheckMate 370). J Thorac Oncol 
2018;13:682-8.
35. Patel SP, Pakkala S, Pennell NA, et al. Phase Ib study of 
crizotinib plus pembrolizumab in patients with previously 
untreated advanced non-small cell lung cancer with ALK 
translocation. Oncologist 2020;25:562-e1012.
36. Felip E, de Braud FG, Maur M, et al. Ceritinib plus 
nivolumab in patients with advanced ALK-rearranged 
non-small cell lung cancer: results of an open-
label, multicenter, phase 1B study. J Thorac Oncol 
2020;15:392-403.
37. Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib 
versus platinum-based chemotherapy in advanced ALK-
rearranged non-small-cell lung cancer (ASCEND-4): 
a randomised, open-label, phase 3 study. Lancet 
2017;389:917-29.
38. Shaw AT, Kim TM, Crinò L, et al. Ceritinib versus 
chemotherapy in patients with ALK-rearranged non-
small-cell lung cancer previously given chemotherapy and 
crizotinib (ASCEND-5): a randomised, controlled, open-
label, phase 3 trial. Lancet Oncol 2017;18:874-86.
39. Kim DW, Gadgeel SM, Gettinger SN, et al. Safety and 
clinical activity results from a phase Ib study of alectinib 
plus atezolizumab in ALK+ advanced NSCLC (aNSCLC). 
J Clin Oncol 2018;36:abstr 9009.
40. Camidge DR, Peters S, Mok T, et al. Updated efficacy 
and safety data from the global phase III ALEX study of 
alectinib (ALC) vs crizotinib (CZ) in untreated advanced 
ALK+ NSCLC. J Clin Oncol 2018;36:abstr 9043.
41. Shaw AT, Lee SH, Ramalingam SS, et al. Avelumab 
(anti–PD-L1) in combination with crizotinib or lorlatinib 
in patients with previously treated advanced NSCLC: 
Phase 1b results from JAVELIN Lung 101. J Clin Oncol 
2018;36:abstr 9008.
42. Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in ROS1-
rearranged advanced non-small-cell lung cancer (NSCLC): 
updated results, including overall survival, from PROFILE 
1001. Ann Oncol 2019;30:1121-6.
43. Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in 
2684 Leone et al. Immunotherapy in fusion-driven NSCLC
© Translational Lung Cancer Research. All rights reserved.   Transl Lung Cancer Res 2020;9(6):2674-2685 | http://dx.doi.org/10.21037/tlcr-20-710
advanced ROS1-positive non-small-cell lung cancer: a 
multicentre, open-label, single-arm, phase 1-2 trial. Lancet 
Oncol 2019;20:1691-701.
44. Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib 
in ROS1 fusion-positive non-small-cell lung cancer: 
integrated analysis of three phase 1-2 trials. Lancet Oncol 
2020;21:261-70.
45. Cho BC, Drilon AE, Doebele RC, et al. Safety and 
preliminary clinical activity of repotrectinib in patients 
with advanced ROS1 fusion-positive non-small cell lung 
cancer (TRIDENT-1 study). J Clin Oncol  
2019;37:abstr 9011.
46. Katayama R, Gong B, Togashi N, et al. The new-
generation selective ROS1/NTRK inhibitor DS-6051b 
overcomes crizotinib resistant ROS1-G2032R mutation in 
preclinical models. Nat Commun 2019;10:3604.
47. Rangachari D, VanderLaan PA, Shea M, et al. Correlation 
between classic driver oncogene mutations in EGFR, 
ALK, or ROS1 and 22C3-PD-L1 ≥50% expression in 
lung adenocarcinoma. J Thorac Oncol 2017;12:878-83.
48. Karatrasoglou EA, Chatziandreou I, Sakellariou S, 
et al. Association between PD-L1 expression and 
driver gene mutations in non-small cell lung cancer 
patients: correlation with clinical data. Virchows Arch 
2020;477:207-17.
49. Lu C, Dong XR, Zhao J, et al. Association of genetic 
and immuno-characteristics with clinical outcomes in 
patients with RET-rearranged non-small cell lung cancer: 
a retrospective multicenter study. J Hematol Oncol 
2020;13:37.
50. Park S, Ahn BC, Lim SW, et al. Characteristics and 
outcome of ROS1-positive non-small cell lung cancer 
patients in routine clinical practice. J Thorac Oncol 
2018;13:1373-82.
51. Gainor JF, Lee DH, Curigliano G, et al. Clinical activity 
and tolerability of BLU-667, a highly potent and selective 
RET inhibitor, in patients (pts) with advanced RET-
fusion+ non-small cell lung cancer (NSCLC). J Clin Oncol 
2019;37:abstr 9008.
52. Drilon A, Oxnard G, Wirth L, et al. PL02.08 registrational 
results of LIBRETTO-001: a phase 1/2 trial of LOXO-
292 in patients with RET fusion-positive lung cancers. J 
Thorac Oncol 2019;14:S6-7.
53. Schuringa JJ, Wojtachnio K, Hagens W, et al. MEN2A-
RET-induced cellular transformation by activation of 
STAT3. Oncogene 2001;20:5350-8.
54. Castellone MD, Melillo RM. RET-mediated modulation 
of tumor microenvironment and immune response in 
multiple endocrine neoplasia type 2 (MEN2). Endocr 
Relat Cancer 2018;25:T105-19.
55. Song Z, Yu X, Cheng G, et al. Programmed death-ligand 
1 expression associated with molecular characteristics in 
surgically resected lung adenocarcinoma. J Transl Med 
2016;14:188.
56. Offin M, Guo R, Wu SL, et al. Immunophenotype and 
response to immunotherapy of RET-rearranged lung 
cancers. JCO Precis Oncol 2019;3:10.1200/PO.18.00386.
57. Guisier F, Dubos-Arvis C, Viñas F, et al. Efficacy and 
safety of anti-PD-1 immunotherapy in patients with 
advanced NSCLC with BRAF, HER2, or MET mutations 
or RET translocation: GFPC 01-2018. J Thorac Oncol 
2020;15:628-36.
58. Sarfaty M, Moore A, Neiman V, et al. RET fusion lung 
carcinoma: response to therapy and clinical features 
in a case series of 14 patients. Clin Lung Cancer 
2017;18:e223-32.
59. Baglivo S, Ludovini V, Moretti R, et al. RET 
rearrangement as a predictor of unresponsiveness to 
immunotherapy in non-small cell lung cancer: report 
of two cases with review of the literature. Oncol Ther 
2020;8:333-9.
60. Ricciuti B, Brambilla M, Metro G, et al. Targeting NTRK 
fusion in non-small cell lung cancer: rationale and clinical 
evidence. Med Oncol 2017;34:105.
61. Ke H, Shen W, Hu A, et al. Distribution of NRG1 gene 
fusions in a large population of Chinese patients with 
NSCLC. J Thorac Oncol 2019;14:e263-6.
62. Jonna S, Feldman RA, Swensen J, et al. Detection of 
NRG1 gene fusions in solid tumors. Clin Cancer Res 
2019;25:4966-72. 
63. Qin A, Johnson A, Ross JS, et al. Detection of known 
and novel FGFR fusions in non-small cell lung cancer 
by comprehensive genomic profiling. J Thorac Oncol 
2019;14:54-62. 
64. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib 
in patients with advanced or metastatic NTRK fusion-
positive solid tumours: integrated analysis of three phase 
1-2 trials. Lancet Oncol 2020;21:271-82.
65. Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in 
patients with TRK fusion-positive solid tumours: a pooled 
analysis of three phase 1/2 clinical trials. Lancet Oncol 
2020;21:531-40.
66. Wang W, Xu C, Chen Y, et al. MET gene fusions in non-
small cell lung cancer (NSCLC) in the Chinese population: 
a multicenter study. J Clin Oncol 2018;36:e13539. 
67. Davies KD, Ng TL, Estrada-Bernal A, et al. Dramatic 
2685Translational Lung Cancer Research, Vol 9, No 6 December 2020
© Translational Lung Cancer Research. All rights reserved.   Transl Lung Cancer Res 2020;9(6):2674-2685 | http://dx.doi.org/10.21037/tlcr-20-710
response to crizotinib in a patient with lung cancer positive 
for an HLA-DRB1-MET gene fusion. JCO Precis Oncol 
2017. doi: 10.1200/PO.17.00117.
68. Gow CH, Liu YN, Li HY, et al. Oncogenic function of a 
KIF5B-MET fusion variant in non-small cell lung cancer. 
Neoplasia 2018;20:838-47.
69. Ou SHI, Sokol ES, Trabucco SE, et al. NTRK1-3 
genomic fusions in non-small cell lung cancer (NSCLC) 
determined by comprehensive genomic profiling. Ann 
Oncol 2019;30:v638.
70. Skoulidis F, Goldberg ME, Greenawalt DM, et al. 
STK11/LKB1 mutations and PD-1 inhibitor resistance 
in KRAS-mutant lung adenocarcinoma. Cancer Discov 
2018;8:822-35. 
71. Duruisseaux M, Drilon A, Han JY, et al. NRG1 fusion-
positive lung cancers: clinicopathologic profile and 
treatment outcomes from a global multicenter registry. 
Eur Respir J 2019;54:PA3666.
72. Saigi M, Alburquerque-Bejar JJ, Mc Leer-Florin A, et 
al. MET-oncogenic and JAK2-inactivating alterations 
are independent factors that affect regulation of PD-L1 
expression in lung cancer. Clin Cancer Res 2018;24:4579-87.
73. Albitar M, Sudarsanam S, Ma W, et al. Correlation of 
MET gene amplification and TP53 mutation with PD-
L1 expression in non-small cell lung cancer. Oncotarget 
2018;9:13682-93.
74. Wang D, Saga Y, Sato N, et al. The hepatocyte growth 
factor antagonist NK4 inhibits indoleamine-2,3-
dioxygenase expression via the c-Met-phosphatidylinositol 
3-kinase-AKT signaling pathway. Int J Oncol 
2016;48:2303-9.
75. Frumento G, Rotondo R, Tonetti M, et al. Tryptophan-
derived catabolites are responsible for inhibition of t and 
natural killer cell proliferation induced by indoleamine 
2,3-dioxygenase. J Exp Med 2002;196:459-68.
76. Titmarsh HF, O'Connor R, Dhaliwal K, et al. The 
emerging role of the c-MET-HGF axis in non-small lung 
cancer tumor immunology and immunotherapy. Front 
Oncol 2020;10:54.
77. Sabari JK, Leonardi GC, Shu CA, et al. PD-L1 expression, 
tumor mutational burden, and response to immunotherapy 
in patients with MET exon 14 altered lung cancers. Ann 
Oncol 2018;29:2085-91. 
78. Reis H, Metzenmacher M, Goetz M, et al. MET 
expression in advanced non-small-cell lung cancer: effect 
on clinical outcomes of chemotherapy, targeted therapy, 
and immunotherapy. Clin Lung Cancer 2018;19:e441-63. 
79. Gainor JF, Rizvi H, Jimenez Aguilar E, et al. Clinical 
activity of programmed cell death 1 (PD-1) blockade 
in never, light, and heavy smokers with non-small-cell 
lung cancer and PD-L1 expression >50%. Ann Oncol 
2020;31:404-11.
80. Gainor JF, Dardaei L, Yoda S, et al. Molecular 
mechanisms of resistance to first- and second-generation 
ALK inhibitors in ALK-rearranged lung cancer. Cancer 
Discov 2016;6:1118-33.
81. Yoda S, Lin JJ, Lawrence MS, et al. Sequential ALK 
inhibitors can select for lorlatinib-resistant compound 
ALK mutations in ALK-positive lung cancer. Cancer 
Discov 2018;8:714-29. 
82. Lin JJ, Zhu VW, Yoda S, et al. Impact of EML4-ALK 
variant on resistance mechanisms and clinical outcomes in 
ALK-positive lung cancer. J Clin Oncol 2018;36:1199-206.
83. Shaw AT, Solomon BJ, Besse B, et al. ALK resistance 
mutations and efficacy of lorlatinib in advanced anaplastic 
lymphoma kinase-positive non-small-cell lung cancer. J 
Clin Oncol 2019;37:1370-9.
Cite this article as: Leone G, Passiglia F, Bironzo P, Bertaglia V, 
Novello S. Is there any place for immune-checkpoint inhibitors 
in the treatment algorithm of fusion-driven non-small cell 
lung cancer?—a literature review. Transl Lung Cancer Res 
2020;9(6):2674-2685. doi: 10.21037/tlcr-20-710
